15-Year safety check for experimental cell therapy

NCT ID NCT07577583

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 32 people who received Azer-Cel, an experimental cell therapy for B-cell related autoimmune diseases, to monitor long-term safety for up to 15 years. Participants are checked for serious side effects and disease changes. The goal is to understand risks over time, not to test new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MEDIATED AUTOIMMUNE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••